XML 15 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Mar. 20, 2026
Jun. 30, 2025
Cover [Abstract]        
Document Type 10-K      
Amendment Flag false      
Document Annual Report true      
Document Transition Report false      
Document Period End Date Dec. 31, 2025      
Document Fiscal Period Focus FY      
Document Fiscal Year Focus 2025      
Current Fiscal Year End Date --12-31      
Entity File Number 001-40789      
Entity Registrant Name CALIDI BIOTHERAPEUTICS, INC.      
Entity Central Index Key 0001855485      
Entity Tax Identification Number 86-2967193      
Entity Incorporation, State or Country Code DE      
Entity Address, Address Line One 4475 Executive Drive      
Entity Address, Address Line Two Suite 200      
Entity Address, City or Town San Diego      
Entity Address, State or Province CA      
Entity Address, Postal Zip Code 92121      
City Area Code (858)      
Local Phone Number 794-9600      
Title of 12(b) Security Common Stock, par value $0.0001 per share      
Trading Symbol CLDI      
Security Exchange Name NYSEAMER      
Entity Well-known Seasoned Issuer No      
Entity Voluntary Filers No      
Entity Current Reporting Status Yes      
Entity Interactive Data Current Yes      
Entity Filer Category Non-accelerated Filer      
Entity Small Business true      
Entity Emerging Growth Company true      
Elected Not To Use the Extended Transition Period false      
Entity Shell Company false      
Entity Public Float       $ 8.0
Entity Common Stock, Shares Outstanding     10,895,725  
Documents Incorporated by Reference [Text Block] None      
ICFR Auditor Attestation Flag false      
Document Financial Statement Error Correction [Flag] false      
Auditor Firm ID 199 688    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheet of Calidi Biotherapeutics, Inc. (the “Company”) as of December 31, 2025 , the related consolidated statements of operations, comprehensive loss, total equity and cash flows for the year ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.      
Auditor Name CBIZ CPAs P.C Marcum LLP    
Auditor Location Costa Mesa, California Costa Mesa, California